Broad-based growth across segments drove a beat on Q4 17 guidance and expectations for Qiagen (both top-line and earnings). With all growth drivers ramping up nicely, the outlook continues to look promising. While the acquisition of Stat-Dx and a one-time headwind from the US tax reforms translate into near-term earnings dilution, the longer-term target of >10% average EPS growth remains unchallenged. We reset our estimates a tad higher and re-iterate our ‘Buy’ recommendation o
13 Feb 2018
Strong end to the year; growth drivers thriving
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong end to the year; growth drivers thriving
Broad-based growth across segments drove a beat on Q4 17 guidance and expectations for Qiagen (both top-line and earnings). With all growth drivers ramping up nicely, the outlook continues to look promising. While the acquisition of Stat-Dx and a one-time headwind from the US tax reforms translate into near-term earnings dilution, the longer-term target of >10% average EPS growth remains unchallenged. We reset our estimates a tad higher and re-iterate our ‘Buy’ recommendation o